- Home
- INCY vs BXP Comparison
INCY vs BXP Comparison
Compare INCY & BXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- BXP
- Stock Information
- Founded
- INCY 1991
- BXP 1970
- Country
- INCY United States
- BXP United States
- Employees
- INCY N/A
- BXP N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- BXP Real Estate Investment Trusts
- Sector
- INCY Health Care
- BXP Real Estate
- Exchange
- INCY Nasdaq
- BXP Nasdaq
- Market Cap
- INCY 13.0B
- BXP 10.4B
- IPO Year
- INCY 1993
- BXP 1997
- Fundamental
- Price
- INCY $86.92
- BXP $65.47
- Analyst Decision
- INCY Buy
- BXP Buy
- Analyst Count
- INCY 20
- BXP 15
- Target Price
- INCY $79.06
- BXP $77.07
- AVG Volume (30 Days)
- INCY 1.9M
- BXP 1.8M
- Earning Date
- INCY 07-29-2025
- BXP 07-29-2025
- Dividend Yield
- INCY N/A
- BXP 5.99%
- EPS Growth
- INCY 900.04
- BXP N/A
- EPS
- INCY 4.37
- BXP 0.03
- Revenue
- INCY $4,584,996,000.00
- BXP $3,410,208,000.00
- Revenue This Year
- INCY $13.53
- BXP $2.53
- Revenue Next Year
- INCY $10.38
- BXP $2.89
- P/E Ratio
- INCY $19.90
- BXP $2,344.48
- Revenue Growth
- INCY 18.87
- BXP 2.91
- 52 Week Low
- INCY $53.56
- BXP $54.22
- 52 Week High
- INCY $87.06
- BXP $90.11
- Technical
- Relative Strength Index (RSI)
- INCY 80.83
- BXP 44.96
- Support Level
- INCY $76.45
- BXP $61.99
- Resistance Level
- INCY $79.43
- BXP $65.71
- Average True Range (ATR)
- INCY 2.57
- BXP 1.91
- MACD
- INCY 1.01
- BXP -0.10
- Stochastic Oscillator
- INCY 99.13
- BXP 40.00
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About BXP Boston Properties Inc.
BXP Inc. owns over 180 properties consisting of approximately 53 million rentable square feet of space. The portfolio is dominated by office buildings and is spread across major cities such as New York, Boston, San Francisco, Los Angeles, Seattle, and the Washington, D.C., region. The real estate investment trust also owns limited retail, hotel, and residential properties.